Clinical Trial Update: Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating belzutifan for recurrent clear cell carcinoma of gynecologic origin is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Gynecologic Cancer
• Ovarian Cancer
• Uterine Cancer
• Vaginal Cancer
• Vulvar Cancer

Drugs mentioned

• Belzutifan (belzutifan)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 2 | Status: RECRUITING